> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-125/
- Published: 2017-03-05T12:00:00.000Z
- Updated: 2026-09-14T22:09:54.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138132

**Panel to Review OTC Meds for Upset Stomach/Hangovers**  
*Federal Register* Notice: FDA has announced a 4/4 joint meeting of the Nonprescription Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The committees will discuss safety issues associated with over-the-counter analgesic combination products used for upset stomach (i.e., heartburn, nausea, fullness, belching, gas, acid indigestion, and/or sour stomach) and hangover indications under the Internal Analgesic and Antacid monographs. The committees will also be asked to discuss the hangover indication under the Overindulgence, Internal Analgesic, and Stimulant monographs. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-03-03/pdf/2017-04152.pdf?ref=fdaweb.com).

**Technical Amendment on Gastroenterology-urology Devices**  
*Federal Register* final rule technical amendment: FDA has amended the identification of manual gastroenterology-urology surgical instruments and accessories to reflect that the device does not include specialized surgical instrumentation for use with urogynecologic surgical mesh specifically intended for use as an aid in the insertion, placement, fixation, or anchoring of surgical mesh during urogynecologic procedures. The amendments are being made to reflect changes made in the recently issued final reclassification order for specialized surgical instrumentation for use with urogynecologic surgical mesh. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-03-01/pdf/2017-03997.pdf?ref=fdaweb.com).

**FDA Withdraws Approval for Two Animal Drugs**  
*Federal Register* Notice: FDA has withdrawn approval of a new animal drug application and an abbreviated new animal drug application at the sponsors’ requests because the products are no longer manufactured or marketed. Products withdrawn are Baxter Healthcare Aerrane (isoflurane USP) and Hospira’s Ceftiofur (ceftiofur sodium) for injection. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-03-01/pdf/2017-03931.pdf?ref=fdaweb.com).

**FDA Confirms Effective Date on Ozone-depleting Substances**  
*Federal Register* notice: FDA has confirmed the effective date of 2/23 for a direct final rule that removes an “essential use” designation for certain ozone-depleting substances (ODSs) under the Clean Air Act. The action removes the essential-use exemption for sterile aerosol talc administered intrapleurally by thoracoscopy for human use and for metered-dose atropine sulfate aerosol human drugs administered by oral inhalation. FDA is taking this action because alternative products that do not use ODSs are now available and because these products are no longer being marketed in versions that contain ODSs. To view the 10/26/2017 direct final rule, click [here](https://www.gpo.gov/fdsys/pkg/FR-2016-10-26/pdf/2016-25851.pdf?ref=fdaweb.com). To view the current notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-02-28/pdf/2017-03866.pdf?ref=fdaweb.com).